American CryoStem Joins Alliance for Regenerative Medicine

RED BANK, NJ–(Marketwire – Feb 8, 2012) – American CryoStem Corporation (OTCQB: CRYO), a commercial developer, manufacturer and marketer of clinical products and services involving adipose tissue and adipose derived adult stem cells, announced its association with the Alliance for Regenerative Medicine (ARM).

ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. American CryoStem’s decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM’s support of policy efforts toward safe and reliable cellular products.

Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine, commented, “We are delighted to have American CryoStem as part of the Alliance and look forward to working together to advance the field of adipose-derived stem cells for a variety of therapeutic applications.”

ARM’s membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine. American CryoStem has created and commercialized core proprietary products and platforms for processing, storing and quality management of adipose tissue and adipose derived adult stem cells that are broadly relevant to ARM’s membership.

“American CryoStem is committed to working with industry organizations to develop cutting edge adipose tissue based treatments and therapies. One unique component of our clinical laboratory product and service suite is offering individuals the opportunity to cryogenically store their younger, healthier adult stem cells for their own future use in regenerative medicine,” stated John Arnone, American CryoStem CEO. “We are pleased and honored to work with the Alliance for Regenerative Medicine to educate the public and regulators on the safe uses of adult stem cells and their potential life changing applications.”

In support of these goals, the Company recently launched ACS Laboratories, thus expanding its clinical processing technology to companies, institutions and medical professionals. ACS Laboratories offers a wide range of adipose tissue specific services. Through ACS laboratories patented ACSelerate™ cell culture media, a ten product suite, American CryoStem can leverage its technology and products to participate in a broad range of clinical application opportunities.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for adipose (fat) tissue and adipose derived adult stem cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

American CryoStem Completes Cell Processing for Clinical Study

RED BANK, NJ–(Marketwire – Feb 7, 2012) – American CryoStem Corporation (OTCQB: CRYO) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products.

The study involves researching the regenerative function of a conditioned medium obtained from each participant’s adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.

John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, “CRYO’s patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility.”

The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician’s office and sent to CRYO’s laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.

“We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO’s exceptional clinical processing for relevant adult stem cell related products,” said Anthony Dudzinski, COO of American CryoStem. “We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product’s time to market.”

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

For More Information, contact:
Investor Relations
American CryoStem Corporation
188 East Bergen Place, Suite 204
Red Bank, NJ 07701
Phone:732-747-1007
www.americancryostem.com

American CryoStem Launches New Consumer Website Design

RED BANK, NJ–(Marketwire – Jan 19, 2012) – American CryoStem Corporation (OTCQB: CRYO) announced today the launch of the Company’s redesigned website americancryostem.com. The new website is a sophisticated online destination showcasing the Company’s branding and marketing of its core “Collect Process and Store” consumer stem cell service.

The new website experience is centered on providing the consumer simple, easy to read information about Adult Stem Cells and CRYO’s long term adult stem cell storage service currently offered through a national network of physicians. “The decision to redesign the website to be more consumer friendly was an easy decision after CRYO’s successful media campaign launch that attracted over 11,000 new members. From the feedback we received, we knew it was time for an update,” explains Natalia Drulle, Creative Director.

As part of CRYO’s on-going marketing campaign the new site features a live chat function to answer questions concerning the Company’s products and services. “Adding this dynamic feature to the site experience is a useful tool to increase customer support and sales conversion,” says John DiFolco, Director of Marketing. “Our goal is to shorten the sales process and provide instant support as we participate in the Regenerative Medicine market where Adult Stem Cells are frequently the main focus of discussion.”

John Arnone, CEO, stated, “The launch of our new website is another step in offering our products and services directly to the consumer market. Having the ability to educate our clients and then refer them to participating physicians allows us to efficiently deliver our message to targeted areas of the country where our service is being adopted.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.

Does fat flow from the fountain of youth?

Juan Ponce de Leon is best known for his search for the fountain of youth. Though this story is probably more fiction than fact, and was attributed to him only after his death, the legend of the fountain of youth and the quest for it have persisted since the 16th century. It has proven to be as elusive as the Holy Grail.

I hear a lot of baby boomers (of which I am one) talk about aging and the quest to maintain their youthful look, mind and health. If only there was a magic elixir for the myriad problems we face in our advancing age. Well, perhaps there is something that can turn back the hands of time to some extent, a little bit of the fountain of youth if you will.

Adipose tissue has been found to be an easily accessible, abundant source of adult stem cells. These stem cells can be used to treat a broad range of medical and cosmetic conditions. If you look at our Resource Library, you’ll see a sampling of the potential applications of adipose derived stem cells, from growing new bone to aiding reconstructive procedures to mitigating the symptoms of multiple sclerosis. And, yes, adipose derived stem cells can help us look youthful too. You can have lipofilling and lipostructuring performed anywhere on your body. Isn’t this a dream come true? Take your fat from a place you don’t want it and put it somewhere you do! Who of us wouldn’t like to remove a few pounds of avoir du pois and apply it elsewhere?

All joking aside, the potential future medical applications for adipose derived stem cells are profound, and they are not that far off. Now is the dawn of the era of regenerative and personalized medicine. Most countries outside of the United States are already using adult stem cells to treat patients with myocardial infarctions, fistulizing Crohn’s disease, and to grow organs. Medical tourism, traveling to other countries to take advantage of treatments not yet routinely available in the United States, has become a booming industry in part because of regenerative and personalized medicine. It is only a matter of time before these therapies become available in the U.S.

So this brings to mind a question. What can I do now to prepare? Speaking for myself, I already have an answer. I will store my adult stem cells in the hope of using them later in the event of a medical ailment, or, in a more vain moment, when I want to reverse the visible “hands of time” with a cosmetic treatment. Not only will I store my own adult stem cells, but I will encourage my children to store theirs as well. After all, that one umbilical cord blood sample I keep may not be useful for all three of them, so why leave anything to chance? It is a bio-insurance that will give me some peace of mind as a mother. It is also a gift I will be giving to family and loved ones. What about you?

Angela M. Miele, DPM
Medical Science Liaison
American CryoStem